c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 143 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Afatinib Dimaleate
CAS:Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Fórmula:C32H33ClFN5O11Pureza:98.11% - 99.87%Cor e Forma:SolidPeso molecular:718.08Foretinib phosphate
CAS:Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Fórmula:C34H40F2N4O14P2Cor e Forma:SolidPeso molecular:828.65SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFórmula:C32H40ClF2N6O13PPureza:98.07%Cor e Forma:SolidPeso molecular:821.12Ref: TM-T5349
1mg35,00€2mg50,00€5mg74,00€10mg113,00€25mg200,00€50mg333,00€100mg495,00€1mL*10mM (DMSO)102,00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Cor e Forma:SolidPeso molecular:632.65Ref: TM-T3113
2mg39,00€5mg57,00€10mg79,00€25mg133,00€50mg207,00€100mg354,00€500mg848,00€1mL*10mM (DMSO)79,00€Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Fórmula:C23H19Cl2FN6OPureza:98.80%Cor e Forma:SolidPeso molecular:485.34Ref: TM-T4260
2mg34,00€5mg49,00€10mg64,00€25mg84,00€50mg92,00€100mg126,00€500mg303,00€1mL*10mM (DMSO)58,00€BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Fórmula:C25H16F2N4O3Pureza:98.33%Cor e Forma:SolidPeso molecular:458.42Ref: TM-T8326
1mg67,00€2mg88,00€5mg148,00€10mg230,00€25mg430,00€50mg622,00€100mg898,00€1mL*10mM (DMSO)170,00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Fórmula:C19H16N8OPureza:98.41% - 98.55%Cor e Forma:SolidPeso molecular:372.38BMS817378
CAS:BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Fórmula:C24H18ClF2N4O7PPureza:>99.99%Cor e Forma:SolidPeso molecular:578.85S49076 HCl
CAS:S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Fórmula:C22H18ClN3O5Pureza:98%Cor e Forma:SolidPeso molecular:439.85Merestinib dihydrochloride
CAS:Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.Fórmula:C30H24Cl2F2N6O3Cor e Forma:SolidPeso molecular:625.45Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Cor e Forma:SolidPeso molecular:510.46Pamufetinib mesylate
CAS:Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Fórmula:C28H27FN4O7S2Pureza:98.91%Cor e Forma:SolidPeso molecular:614.67Tivantinib
CAS:Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Fórmula:C23H19N3O2Pureza:98% - 99.41%Cor e Forma:SolidPeso molecular:369.42Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C31H29FN4O5Pureza:99.95% - 99.98%Cor e Forma:SolidPeso molecular:556.58NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Fórmula:C20H16N6Pureza:97.24% - >99.99%Cor e Forma:SolidPeso molecular:340.38Ref: TM-T2680
2mg44,00€5mg74,00€10mg97,00€25mg178,00€50mg255,00€100mg359,00€200mg510,00€1mL*10mM (DMSO)84,00€Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H21Cl2FN6O2Pureza:99.77%Cor e Forma:SolidPeso molecular:503.36Ref: TM-T8825
2mg34,00€5mg48,00€10mg63,00€25mg84,00€50mg92,00€100mg126,00€500mg250,00€1mL*10mM (DMSO)50,00€NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Fórmula:C31H23F2N5O3Pureza:98.48%Cor e Forma:SolidPeso molecular:551.54Ref: TM-T6907
1mg34,00€2mg46,00€5mg66,00€10mg92,00€25mg167,00€50mg245,00€100mg356,00€200mg530,00€1mL*10mM (DMSO)82,00€Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Fórmula:C17H13BrN2Pureza:97.67%Cor e Forma:SolidPeso molecular:325.2Ref: TM-T25492
1mg35,00€2mg52,00€5mg80,00€10mg119,00€25mg231,00€50mg344,00€100mg480,00€200mg663,00€1mL*10mM (DMSO)92,00€AMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Fórmula:C23H22FN7O3Pureza:99.26% - 99.9%Cor e Forma:SolidPeso molecular:463.46Ref: TM-T3209
1mg40,00€2mg52,00€5mg85,00€10mg124,00€25mg197,00€50mg350,00€100mg522,00€200mg748,00€1mL*10mM (DMSO)86,00€X-376
CAS:X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.Fórmula:C25H25Cl2FN6O3Pureza:97.87%Cor e Forma:SolidPeso molecular:547.41Ref: TM-T3550
1mg35,00€2mg50,00€5mg87,00€10mg119,00€25mg258,00€50mg427,00€100mg582,00€1mL*10mM (DMSO)105,00€
